With a new healthcare bill (and its “fixes”) signed into law, one might think that the biotech industry could shift its attention away from Washington DC and get back to work in the labs. That would be wrong. Starting this month, we begin a two-year project that will culminate, if things go according to plan, … Continue reading “The Next Policy Battle For Biotech After Healthcare Reform”
Author: Richard Pops
Richard Pops serves as Chairman, President and Chief Executive Officer of Waltham, MA-based Alkermes. He assumed the role of Chairman of the Board in April 2007 and he previously served as Chief Executive Officer of Alkermes from February 1991 through April 2007. Under his leadership, Alkermes has grown from a privately held company with 25 employees to a publicly traded pharmaceutical company with more than 500 employees and two commercial products. Mr. Pops currently serves on the Board of Directors of: Alkermes, Inc.; Neurocrine Biosciences, Inc.; Acceleron Pharma, Inc.; Epizyme; the Biotechnology Industry Organization (BIO); the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Harvard Medical School Board of Fellows.